Back grey_arrow_rt.gif
New Regenerative Diabetes Therapy: stimulates the growth of new insulin producing islet cells in the pancreas
  Sanofi-aventis, CureDM enter $335-million deal for diabetes th erapy
by Matthew Dennis,
Last Updated:April 08, 2010 10:54
Sanofi-aventis signed an agreement Thursday gaining an exclusive worldwide license to CureDM's experimental diabetes therapy Pancreate (proisletide) under a deal that could be worth up to $335 million for the biopharmaceutical company. Marc Cluzel, executive vice president of R&D at sanofi-aventis, said that "once fully developed, Pancreate has the potential to become the first regenerative treatment of type 1 and type 2 diabetes." The naturally occurring human protein, which has been shown in preclinical studies to stimulate the growth of new insulin producing islet cells in the pancreas, is expected to enter Phase I development later this year, the company noted.
Under the agreed terms, sanofi-aventis will make an upfront and milestone payments to CureDM, as well as royalties on global sales, if the compound is approved.
Reference Articles
Sanofi, CureDM sign license accord on diabetes treatment - (Bloomberg)
Sanofi signs $335 mln exclusive diabetes deal - (CNBC)
Sanofi-Aventis buys rights to CureDM diabetes treatment for up to $335M - (Philadelphia Business Journal)
Sanofi expands diabetes efforts (free preview) - (The Wall Street Journal)
Sanofi-aventis and CureDM sign exclusive worldwide license agreement on novel regenerative compound to treat diabetes - (sanofi-aventis)
  icon paper stack View Older Articles   Back to Top